Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients

PURPOSE: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term survival gains are controversial owing to distin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Jean, Lee, Hyouk Jin, Nam, Seok Jin, Lee, Soo Jung, Jung, Jin Hyang, Jung, Sung Hoo, Lim, Seung Taek, Jeon, Ye Won, Gwak, Hongki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311364/
https://www.ncbi.nlm.nih.gov/pubmed/32595988
http://dx.doi.org/10.4048/jbc.2020.23.e34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311364/
https://www.ncbi.nlm.nih.gov/pubmed/32595988
http://dx.doi.org/10.4048/jbc.2020.23.e34

Ejemplares similares